07:00 , May 19, 2016 |  BC Innovations  |  Finance

Found in translation

Mark Zipkin, Staff Writer  With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Financial News

Genkyotex completes venture financing

Genkyotex S.A. , Plan-les-Ouates, Switzerland   Business: Renal, Hepatic, Pulmonary   Date completed: 2015-01-07   Type: Venture financing   Raised: CHF20 million ($19.9 million)   Investors: NeoMed; VI Partners; Biomed Invest; Edmond de Rothschild Investment...
07:00 , May 12, 2014 |  BioCentury  |  Emerging Company Profile

Inotrem: Sepsis companion

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug...
07:00 , Mar 24, 2014 |  BioCentury  |  Finance

Modulating sepsis

Modulating sepsis Sepsis is among the most intractable indications in drug development, but Inotrem S.A. and its series A investors think the company's peptide inhibitors of TREM1 may succeed where all others have failed. New...
23:39 , Mar 13, 2014 |  BC Extra  |  Financial News

Inotrem raises EUR 18 million series A

Inotrem S.A. (Nancy, France) raised EUR 18 million ($25 million) in a series A round co-led by new investors Edmond de Rothschild Investment Partners (EdRIP) and Sofinnova Partners. New investors Biomed Invest and the French...
07:00 , Sep 27, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Glycart Biotechnology AG Zurich, Switzerland Technology: Fc carbohydrate engineering of therapeutic antibodies to increase cell killing ability Disease focus: Cancer and autoimmune disease Clinical status: Phase I/II Founded: 2001 by Pablo Umana, Joel Jean-Mairet and...